期刊文献+

吉非替尼联合鸦胆子油乳对肺腺癌细胞的作用及其机制 被引量:5

Effects of Gefitinib Combined with Bruceolic Oil Emulsion on Human Lung Adenocarcinoma Cell Lines and Its Mechanism
下载PDF
导出
摘要 目的探讨吉非替尼(Gefitinib,G)联合鸦胆子油乳(Bruceolic oil emulsion,B)对肺腺癌PC-9、A549细胞增殖与凋亡的作用及其机制。方法取对数生长期的PC-9、A549细胞进行实验,两细胞株在实验中均分为对照组和实验组。采用MTT比色法、TUNEL法及流式细胞技术检测各实验组对肺腺癌细胞的增殖抑制、诱导细胞凋亡及细胞周期阻滞等作用。结果吉非替尼、鸦胆子油乳单药均能抑制PC-9、A549细胞的生长、增殖并诱导其凋亡,呈浓度和时间依赖效应。与鸦胆子油乳联合后,吉非替尼对PC-9和A549细胞的IC50较单用时分别下降了50.72%和66.56%。两药联合后对两细胞的增殖抑制及凋亡诱导作用进一步增强。结论吉非替尼联合鸦胆子油乳能显著抑制肺腺癌PC-9、A549细胞增殖、诱导细胞凋亡,可能与药物对细胞周期的阻滞作用有关。两者合用时鸦胆子油乳可对吉非替尼起到增效增敏的作用。 Objective To investigate the effects of gefitinib combined with bruceolic oil emulsion on the proliferation and apoptosis of human lung adenocarcinoma cell lines PC-9 and A549 and related mechanism. Methods PC-9 and A549 cell lines in logarithmic phase were divided into control group and experimental groups. MTT colorimetry, TUNEL assay and flow cytometry were used to detect the effects of gefitinib combined with bruceolic oil emulsion on cell proliferation, cell apoptosis and cell cycle in the experimental groups. Results Gefitinib and Bruceolic oil emulsion could inhibit the growth, proliferation and increase the apoptosis of PC-9 and A549 cell lines in a dose- and time-dependent manner. The growth inhibitory and apoptotic effects of the concomitant administration of gefitinib and bruceolic oil emulsion were higher than other groups. Conclusion Gefitinib and Bruceolic oil emulsion could significantly inhibit the proliferation and induce the apoptosis of PC-9 and A549 cell lines. The effects might be related to the retardation of drugs on cell cycle. Bruceolic oil emulsion has a synergy-increasing effect to gefitinib.
作者 张楚 王琳
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2015年第10期965-969,共5页 Cancer Research on Prevention and Treatment
关键词 吉非替尼 鸦胆子油乳 肺腺癌 细胞增殖 细胞凋亡 细胞周期 Gefitinib Bruceolic oil emulsion Lung adenocarcinoma Cell proliferation Cell apoptosis Cell cycle
  • 相关文献

参考文献5

  • 1Kris Mark G,Natale Ronald B,Herbst Roy S,Lynch Thomas J,Prager Diane,Belani Chandra P,Schiller Joan H,Kelly Karen,Spiridonidis Harris,Sandler Alan,Albain Kathy S,Cella David,Wolf Michael K,Averbuch Steven D,Ochs Judith J,Kay Andrea C.Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA : the journal of the American Medical Association . 2003
  • 2Jemal Ahmedin,Siegel Rebecca,Xu Jiaquan,Ward Elizabeth.Cancer statistics, 2010. CA: a cancer journal for clinicians . 2010
  • 3Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology . 2003
  • 4Masahiro Fukuoka,Yi-Long Wu,Sumitra Thongprasert,Patrapim Sunpaweravong,Swan-Swan Leong,Virote Sriuranpong,Tsu-Yi Chao,Kazuhiko Nakagawa,Da-Tong Chu,Nagahiro Saijo,Emma L. Duffield,Yuri Rukazenkov,Georgina Speake,Haiyi Jiang,Al.Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS). Japanese Journal of Clinical Oncology . 2011
  • 5Maemondo Makoto,Inoue Akira,Kobayashi Kunihiko,Sugawara Shunichi,Oizumi Satoshi,Isobe Hiroshi,Gemma Akihiko,Harada Masao,Yoshizawa Hirohisa,Kinoshita Ichiro,Fujita Yuka,Okinaga Shoji,Hirano Haruto,Yoshimori Kozo,Harada Toshiyuki,Ogura Takas.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England Quarterly . 2010

共引文献11

同被引文献65

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部